AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.
New therapeutic target for treating nonalcoholic steatohepatitis (NASH) and fatty liver disease
Summary
Rudolph L Leibel, M.D.
Technology Benefits
Provides a target for NASH therapeutic developmentProvides a target for dyslipidemia therapeutic developmentPatent information:N/ATech Ventures Reference: IR CU13175
Technology Application
Pharmaceutical activators of ILDR2 may reduce lipid accumulation in the liver to treat NASH patients.ILDR2 alters lipoprotein metabolism and may be used to treat dyslipidemia and atherosclerosis. Characterization of ILDR2 suggests a role in preservation of beta cell mass, and control of body weight.
Detailed Technology Description
Rudolph L Leibel, M.D.
Country/Region
USA
For more information, please click Here
